This far it only works in blood cancers, specifically B cell lymphomas. The approved CAR-Ts target a molecule called CD19 expressed on B cells
It has not worked widely in solid tumors for a variety of reasons, including immune suppression within the tumor microenvironemnt and difficulty finding antigens that are widely expressed on tumors but not also expressed on healthy cells (so you don't kill healthy tissue in addition to the tumor)
It has not worked widely in solid tumors for a variety of reasons, including immune suppression within the tumor microenvironemnt and difficulty finding antigens that are widely expressed on tumors but not also expressed on healthy cells (so you don't kill healthy tissue in addition to the tumor)